Coronavirus: BioNTech chooses Singapore as its Asia Pacific vaccine hub

May 10, 2021 | INVESTING

German drug maker BioNTech, whose coronavirus vaccine with Pfizer was the first to be approved in the United States and Europe for use last year, on Monday announced a new manufacturing facility in Singapore that would produce “several hundreds of millions” of mRNA-based vaccine doses a year.The move will boost BioNTech’s production capacities for vaccines and therapeutics for infectious diseases and cancer, and ensure it has rapid-response production capability for potential pandemic threats…

Read More

Pin It on Pinterest